WHO grants full manufacturing prequalification for Biological E polio vaccine
Approval enables end-to-end vaccine production at single site
Change
The WHO granted Phase II prequalification to Biological E for full manufacturing of its oral polio vaccine.
Why it matters
The approval covers both drug substance and drug product at a single integrated facility, expanding the company’s qualified manufacturing scope. It enables full-cycle production for global supply programmes.
Implications
- — Vaccine manufacturers must align supply planning with expanded capacity — failure risks missed procurement opportunities
- — Global health procurement teams must update supplier eligibility lists — delays risk supply gaps
Full decision brief
See the decision layer
Use 1 free preview to unlock implications, who’s affected, what to watch, and Clarify for this brief.
2 free previews left this month · Resets 1 Jun
Source